Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy
暂无分享,去创建一个
[1] C. Weyer,et al. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. , 2003, Metabolism: clinical and experimental.
[2] J. Gosden,et al. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. , 2009, British journal of clinical pharmacology.
[3] E. Bush,et al. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. , 2004, European journal of pharmacology.
[4] W. Edwards,et al. Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.
[5] N. Moore,et al. New central targets for the treatment of obesity. , 2009, British journal of clinical pharmacology.
[6] M. Cowley,et al. Inhibition of Dopamine and Norepinephrine Reuptake Produces Additive Effects on Energy Balance in Lean and Obese Mice , 2007, Neuropsychopharmacology.
[7] F. Cavagnini,et al. Growth hormone in obesity , 1999, International Journal of Obesity.
[8] Christoph Beglinger,et al. Effect of peptide YY3-36 on food intake in humans. , 2005, Gastroenterology.
[9] E. Zorrilla,et al. Vaccination against weight gain , 2006, Proceedings of the National Academy of Sciences.
[10] J. Geddes,et al. What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.
[11] H. Gurtner. Aminorex and pulmonary hypertension. A review. , 1985, Cor et vasa.
[12] T. Moran,et al. Minireview: Gut peptides: targets for antiobesity drug development? , 2009, Endocrinology.
[13] B. Ellenbroek,et al. The histamine H3 receptor as a therapeutic drug target for CNS disorders. , 2009, Drug discovery today.
[14] K. Gadde,et al. Rational Design of a Combination Medication for the Treatment of Obesity , 2009, Obesity.
[15] G. Frost,et al. Pancreatic polypeptide reduces appetite and food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.
[16] T Brott,et al. Phenylpropanolamine and the risk of hemorrhagic stroke. , 2000, The New England journal of medicine.
[17] B. Lowell,et al. Adipose tissue mass can be regulated through the vasculature , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[18] S. Heymsfield,et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. , 2007, The Journal of clinical endocrinology and metabolism.
[19] R. Phillips,et al. Common dietary supplements for weight loss. , 2004, American family physician.
[20] G. Frost,et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial , 2006, International Journal of Obesity.
[21] Christian Weyer,et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies , 2008, Proceedings of the National Academy of Sciences.
[22] M. Jensen,et al. Effects of growth hormone administration in human obesity. , 2003, Obesity research.
[23] Mohammad A Ghatei,et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. , 2004, Endocrinology.
[24] G. Bray,et al. Pharmacological Treatment of the Overweight Patient , 2007, Pharmacological Reviews.
[25] D. Larhammar. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide , 1996, Regulatory Peptides.
[26] Andrew A. Young,et al. Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin , 1996 .
[27] N. Benowitz,et al. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. , 2001, The New England journal of medicine.
[28] P. Sucharda,et al. Angiogenic factors are elevated in overweight and obese individuals , 2005, International Journal of Obesity.
[29] Noboru Murakami,et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. , 2002, Gastroenterology.
[30] J. Goldstein,et al. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides , 2008, Proceedings of the National Academy of Sciences.
[31] Bengt Långström,et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. , 2006, Cell metabolism.
[32] M. Lesch,et al. Sudden death associated with thyroid hormone abuse. , 1981, The American journal of medicine.
[33] Jason Chung,et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. , 2009, Cell metabolism.
[34] M. Zarrindast,et al. Anorectic and behavioural effects of bupropion. , 1988, General pharmacology.